Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-6 of  6 results for ""Drugs, Essential""

Your Filters

Filter by : Subject Publication : expert review of pharmacoeconomics outcomes research
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.

  • Authors : Pyadushkina E; Autonomous Nonprofit Organization 'National Center for Health Technology Assessment', Moscow, Russian Federation.; Derkach E

Subjects: HIV-1*/HIV-1*/HIV-1*/genetics ; Drugs, Essential* ; HIV Infections*/HIV Infections*/HIV Infections*/drug therapy

  • Source: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2022 Dec; Vol. 22 (8), pp. 1215-1220. Date of Electronic Publication: 2022 Oct 05.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis.

  • Authors : Dilokthornsakul P; Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.; Permsuwan U

Subjects: Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/drug therapy ; Factor Xa Inhibitors*/Factor Xa Inhibitors*/Factor Xa Inhibitors*/economics ; Factor Xa Inhibitors*/Factor Xa Inhibitors*/Factor Xa Inhibitors*/therapeutic use

  • Source: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2022 Jan; Vol. 22 (1), pp. 93-100. Date of Electronic Publication: 2021 Feb 10.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Can we achieve affordable cancer medicine prices? Developing a pathway for change.

  • Authors : Vogler S; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute), Vienna, Austria.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*economics ; Neoplasms/Neoplasms/Neoplasms/*drug therapy; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/administration & dosage

  • Source: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2021 Jun; Vol. 21 (3), pp. 321-325. Date of Electronic Publication: 2021 Mar 12.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Rational use effects of implementing an essential medicines list in West Bank, Palestinian Territories.

  • Authors : Younis MZ; School of Health Sciences, Jackson State University, 350 West Woodrow Wilson Drive, Jackson, MS 39213 USA. ; Hamidi S

Subjects: Drugs, Essential/Drugs, Essential/Drugs, Essential/*therapeutic use ; Practice Patterns, Physicians'/Practice Patterns, Physicians'/Practice Patterns, Physicians'/*standards ; Prescription Drugs/Prescription Drugs/Prescription Drugs/*therapeutic use

  • Source: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2009 Jun; Vol. 9 (3), pp. 243-50.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print Cited Medium: Internet ISSN: 1744-8379

Record details

Read More Add to Saved list
×
Academic Journal

Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis.

  • Authors : Liu J; a School of Medicine and Health Management, Tongji Medical College , Huazhong University of Science and Technology , Wuhan City , Hubei Province , China.; Wang L

Subjects: Drug Costs/Drug Costs/Drug Costs/*legislation & jurisprudence ; Drugs, Essential/Drugs, Essential/Drugs, Essential/*economics ; Drugs, Generic/Drugs, Generic/Drugs, Generic/*economics

  • Source: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2017 Dec; Vol. 17 (6), pp. 625-631. Date of Electronic Publication: 2017 May 18.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand.

  • Authors : Thongsri W; a Health Intervention and Technology Assessment Program (HITAP) , Ministry of Public Health , Nonthaburi , Thailand.; b Social and Administrative Pharmacy Excellence Research (SAPER) Unit, Department of Pharmacy, Faculty of Pharmacy , Mahidol University , Bangkok , Thailand.

Subjects: Epoprostenol/Epoprostenol/Epoprostenol/*analogs & derivatives ; Heart Defects, Congenital/Heart Defects, Congenital/Heart Defects, Congenital/*complications ; Hypertension, Pulmonary/Hypertension, Pulmonary/Hypertension, Pulmonary/*drug therapy

  • Source: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2016 Aug; Vol. 16 (4), pp. 525-36. Date of Electronic Publication: 2015 Dec 19.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-6 of  6 results for ""Drugs, Essential""